of metastatic NSCLC patients treated with anti-PD-1 monotherapy also showed that the OSRR was greater in lymph node metastases (OSRR = 28%) compared to other sites, including liver and lung metastases (134). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.